- Prepare accurate financial data, develop rolling forecasts, and analyze trends to support effective resource allocation and financial planning.
- Deliver comprehensive financial reports, dashboards, and KPI analyses to facilitate decision-making and monitor performance metrics.
- Evaluate financial performance through profitability analyses, ROI assessments, and risk identification to support business growth initiatives.
- Develop robust financial models and business proposals to assess investment opportunities and optimize resource deployment.
- Lead the automation and enhancement of FP&A processes and tools, including dashboards, forecasting models, and data integration, to improve analytical capabilities and reporting accuracy.
- Provide timely and accurate financial data for audits, ensuring full compliance with regulatory requirements and internal governance standards.
- Conduct advanced financial modeling and scenario analysis to support strategic planning and business decision-making.
Job Requirements
- From 7 to 10 years of experience in finance and planning.
- Bachelor’s/master’s degree in commerce/business administration / economic with high level of
- Finance & Accounting Experience. Chartered Accountant/MBA/CPA/FPAC/FPAMC is preferred
- Sound knowledge of financial systems (SAP, MS Office and Other financial reporting systems) is an addition.
- Strong technical knowledge and experience of both Management reporting and planning processes
- Good communication skills, Proficiency in English & Arabic language.
About Integrated Diagnostics Holdings - IDH
Hospitality
Giza,
Egypt•
1000+employees
IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan, Nigeria and Saudi Arabia. The Group’s core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Saudi Arabia, Ultralab and Al Mokhtabar in Sudan and Echo Lab in Nigeria. A long track record for quality and safety has earned the company a trusted reputation, as well as internationally recognized accreditations for its portfolio of over 2,000 diagnostics tests. From its base of 538 branches as of 30 June 2022, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group’s expansion plans include acquisitions in new Middle Eastern, African, and East Asian markets where its model is well-suited to capitalize on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a standard listing on the main market of the London Stock Exchange (ticker: IDHC) since May 2015 with a secondary listing on the EGX since May 2021 (ticker: IDHC.CA).